Peptide

Berobenatide

Also known as

PF-08653944 · PF’3944 · MET-097i (Metsera name before Pfizer) · Pfizer monthly GLP-1

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	An investigational injected GLP-1 peptide, also called MET-097i or PF-08653944. People discuss weight loss with weekly treatment followed by potentially monthly injections.
Why it attracts interest	Fewer injection reminders and easier travel are hoped-for conveniences. People disagree about how burdensome weekly shots are.

Notes

MET-097i and PF’3944 are names for the same candidate. Berobenatide, also PF-08653944, activates GLP-1 signaling and is studied as an injection beneath the skin. It is a single GLP-1 agonist, rather than tirzepatide's two-receptor approach or an oral pill. Pfizer VESPER-3 monthly topline results (Official context · Accessed 2026-09-30)

Berobenatide is an investigational GLP-1 peptide discussed for weight loss with fewer injections: weekly initially, then potentially monthly. Trial accounts describe appetite changes, food aversion and a difficult monthly transition. Their assigned treatment and doses remain unverified.

Fewer injections are the practical appeal. A Reddit discussion imagines fewer weekly reminders, travel arrangements and injection-site hassles. Replies disagree about how burdensome weekly shots actually are. The convenience is a hoped-for benefit, not proof that monthly treatment will suit everyone. Once-a-month GLP-1 shots look really promising. (Community discussion · Accessed 2026-09-30)

Source context — Pfizer VESPER-3 monthly topline results: Sponsor-selected interim Phase 2b results. The 12.3% and 10.5% values are different analyses of one arm. No head-to-head tolerability comparison, personal-use recommendation or long-term safety assurance.

Source context — Once-a-month GLP-1 shots look really promising.: Prospective discussion, not personal Berobenatide exposure. Promotional provider mention in another reply excluded. Speculation about microdosing or future implants not treated as a regimen or prediction.

What people notice

Hunger and fullness	A relayed blinded participant described quieter food noise and feeling full sooner. Active treatment and dose were unknown.
Weight and maintenance	Another claimed participant reported 25 lb lost by five weeks, later 85 lb, then difficulty keeping weight toward the upper end of 110–120 lb. This is one evolving, unverified account.

Notes

Less hunger and easier stopping at meals. A German forum article relays one blinded VESPER-4 participant's quieter food noise and earlier fullness. The account cannot confirm active treatment. Berobenatide VESPER-4, Studie, Wirkung und Erfahrung (Secondhand community claim · Accessed 2026-09-30)

Weight loss can also become hard to manage. Reddit author Apprehensive_Rope634 reported 25 lb lost at five weeks and looser clothes. Later, after 85 lb lost, they struggled to stay toward the upper end of 110–120 lb. Early celebration did not mean effortless maintenance. 25lbs down in 5 weeks! Clinical Trial — follow-up and participant replies (Personal report · Accessed 2026-09-30)

OP five-week weight/clothing account; OP weekly-12-weeks/monthly reply and missed-week appetite control; hanuh_conda first-monthly-dose reply; OP later 85-lb and 110–120-lb maintenance reply. 25lbs down in 5 weeks! Clinical Trial — follow-up and participant replies (Personal report · Accessed 2026-09-30)

Source context — Berobenatide VESPER-4, Studie, Wirkung und Erfahrung: One relayed, AI-assisted blinded participant account; original participant thread not opened. Unknown active/placebo assignment and dose. Formal summaries elsewhere in article are not first-person evidence.

Source context — 25lbs down in 5 weeks! Clinical Trial — follow-up and participant replies: Same OP as initial diary; unknown dose and assignment; self-identified Matsera/MAT097. Reply authors' study identity is not independently verified; rough monthly reaction has no symptom description or duration. Relative timestamps not converted to invented dates; some expanded replies unavailable.

Doses people talk about

Community amounts	The inspected diaries do not disclose verified milligrams. Trial-controlled increases cannot supply a personal-use dose range.
Weekly study amounts	0.4, 0.8, 1.2 and 1.6 mg weekly appear in VESPER-2 discussion. A separate VESPER-1 design used 2.4 mg weekly; these remain trial amounts.
Monthly study amounts	VESPER-3 used weekly 0.4–1.2 mg steps before 3.2 or 4.8 mg monthly. These are subcutaneous study quantities per injection, not daily totals or a consumer transition plan.

Notes

No verified personal-use dose range in the inspected diaries. The Reddit participant's trial controlled undisclosed amounts and increases. This does not supply a community dosing chart. Clinical trial. — Apprehensive_Rope634 and replies (Personal report · Accessed 2026-09-30)

0.4, 0.8, 1.2 and 1.6 mg weekly are repeated trial amounts. The Incretins repeats these VESPER-2 diabetes-study arms, not biohacker-established amounts. Monthly quantities remain separately labeled study context below. The Incretins — ADA Conference 2026 (Community guide · Accessed 2026-09-30)

Weekly and monthly quantities belong to different study designs. VESPER-3 used 0.4–1.2 mg weekly steps before 3.2 or 4.8 mg monthly. Pfizer separately discussed 1.6 mg weekly in VESPER-2 and 2.4 mg weekly in VESPER-1. These are per-injection amounts, not daily totals or an interchangeable regimen. Pfizer VESPER-3 monthly topline results (Official context · Accessed 2026-09-30) · Pfizer ADA 2026 VESPER programme results (Official context · Accessed 2026-09-30)

Source context — Clinical trial. — Apprehensive_Rope634 and replies: Self-reported trial participation, misspelled compound identifier, unverified assignment and dose; weaning confounder. Amgen reply is not Berobenatide evidence. Later post is the same OP, not an independent replication.

Source context — The Incretins — ADA Conference 2026: Author commentary and repetition of conference/sponsor data, not a human self-use log or independent half-life measurement. Semaglutide-clone description and superiority inference not adopted. Trial-origin quantities retain their actual origin.

Source context — Pfizer ADA 2026 VESPER programme results: Sponsor-selected conference announcement. VESPER-1 figure is not placebo-adjusted; VESPER-2 is a separate diabetes population. Repetition of VESPER-3 data does not create another source allowance or independent result.

Half-life, onset & duration

Felt onset	One diary described almost no appetite within its first week. It does not establish a predictable first-dose onset, and the assigned treatment was unverified.
Felt duration	The same author reported appetite control nearly two weeks after the last injection when they missed a weekly visit. Prior repeated doses prevent treating this as a single-dose window; full-month coverage remains unclear.
Half-life	About 380 hours, or 15–16 days, after a single subcutaneous dose in preliminary sponsor human data. This is blood elimination, separate from felt appetite control.

Notes

Appetite changes in the first week of one trial diary. After a May 1 first injection, the May 8 post described almost no appetite. Headache around two hours and sulfur burps around 30 hours after injection were adverse-symptom timings, not weight-loss onset measurements. The headache reportedly resolved after drinking water. Clinical trial. — Apprehensive_Rope634 and replies (Personal report · Accessed 2026-09-30)

OP May 1 start and early symptoms; OP 28-day update; Mat097 identification; reply identifying a different Amgen trial. Clinical trial. — Apprehensive_Rope634 and replies (Personal report · Accessed 2026-09-30)

Near two weeks in one missed-dose account; a full month remains unclear. The same author reported appetite control after missing a weekly visit for travel, approaching two weeks since the last injection. Prior repeated doses prevent calling this a single-dose measurement or monthly curve. 25lbs down in 5 weeks! Clinical Trial — follow-up and participant replies (Personal report · Accessed 2026-09-30)

Human half-life: approximately 380 hours, or 15–16 days. Metsera's filing reports this after a single subcutaneous dose. It is a preliminary sponsor result, separate from felt duration. Metsera Form 424B4 — first-in-human MET-097i results (Official context · Accessed 2026-09-30)

Source context — Metsera Form 424B4 — first-in-human MET-097i results: Preliminary sponsor securities disclosure, not a peer-reviewed full human pharmacokinetics paper. Approximately 380 hours refers to human measured elimination, not a monthly feel window. Pig figure not adopted.

Cycles people discuss

Ongoing study use	One diary describes 12 weeks of weekly injections followed by monthly visits. This is a reported maintenance schedule; the records establish no community on/off cycle.

Notes

One diary describes 12 weekly weeks followed by monthly visits. This reported study schedule concerns ongoing maintenance. These reports establish no community on/off cycle. A four-week injection interval is not a four-week course. 25lbs down in 5 weeks! Clinical Trial — follow-up and participant replies (Personal report · Accessed 2026-09-30) · Once-a-month GLP-1 shots look really promising. (Community discussion · Accessed 2026-09-30)

Stacks

No specific combination	The saved record describes berobenatide as the solo GLP-1 in VESPER. Semaglutide and tirzepatide appear as comparisons, without a documented combination.

Notes

Solo GLP-1 in VESPER. [trial]

Comparison, not combination: Semaglutide and tirzepatide appear as alternatives in the discussion, not established berobenatide stacks. [community]

Watch for

Food aversion and gut symptoms	Reports include difficulty tolerating food, queasiness, sulfur burps and fatty-meal heartburn. Trial nausea, vomiting and diarrhea are separately recorded.
Monthly transition varies	One reply called the first monthly dose rough without describing symptoms or duration; the original author felt well. This does not establish how often a difficult transition occurs.
Unapproved candidate	The saved records identify no approved regimen or established community preparation standard. Trial administration does not verify another product's contents or long-term safety.

Notes

A quieter appetite can become food aversion. The early diary describes difficulty finding tolerable foods, brief queasiness and sulfur burps lasting about 24 hours. Recently weaning a child also confounded weight changes. Clinical trial. — Apprehensive_Rope634 and replies (Personal report · Accessed 2026-09-30)

Trial nausea, vomiting and diarrhea still occurred. Pfizer described predominantly mild or moderate events, with severe nausea or vomiting possible. Comparisons with Zepbound from separate trials cannot establish which is better tolerated. Pfizer VESPER-3 monthly topline results (Official context · Accessed 2026-09-30)

The VESPER-4 report is a different, blinded account. The German article relays 93 to 89.2 kg over five weeks, occasional fullness and fatty-meal heartburn. Dose and placebo status were unknown; this AI-assisted retelling cannot establish monthly experience. Berobenatide VESPER-4, Studie, Wirkung und Erfahrung (Secondhand community claim · Accessed 2026-09-30)

The first monthly dose was rough for one reply author. Reply author hanuh_conda called the first monthly dose rough, without specifying symptoms or duration. The original author reported feeling well. These distinct voices show variation, not its frequency. 25lbs down in 5 weeks! Clinical Trial — follow-up and participant replies (Personal report · Accessed 2026-09-30)

No approved regimen or community preparation standard. The existing record identifies an unapproved candidate and no established community preparation guidance. Trial administration does not validate a separately labeled product or establish long-term safety. Pfizer ADA 2026 VESPER programme results (Official context · Accessed 2026-09-30)

Full notes

What the monthly-shot idea means

MET-097i and PF’3944 are names for the same candidate. Berobenatide, also PF-08653944, activates GLP-1 signaling and is studied as an injection beneath the skin. It is a single GLP-1 agonist, rather than tirzepatide's two-receptor approach or an oral pill. Official context
Fewer injections are the practical appeal. A Reddit discussion imagines fewer weekly reminders, travel arrangements and injection-site hassles. Replies disagree about how burdensome weekly shots actually are. The convenience is a hoped-for benefit, not proof that monthly treatment will suit everyone. Reddit r/GLP1ResearchTalk

Benefits people are looking for

Less hunger and easier stopping at meals. A German forum article relays one blinded VESPER-4 participant's quieter food noise and earlier fullness. The account cannot confirm active treatment. GLP-1 Forum Germany
Weight loss can also become hard to manage. Reddit author Apprehensive_Rope634 reported 25 lb lost at five weeks and looser clothes. Later, after 85 lb lost, they struggled to stay toward the upper end of 110–120 lb. Early celebration did not mean effortless maintenance. Personal report

Doses people discuss

No verified personal-use dose range in the inspected diaries. The Reddit participant's trial controlled undisclosed amounts and increases. This does not supply a community dosing chart. Personal report
0.4, 0.8, 1.2 and 1.6 mg weekly are repeated trial amounts. The Incretins repeats these VESPER-2 diabetes-study arms, not biohacker-established amounts. Monthly quantities remain separately labeled study context below. Community guide

Half-life

About 15 days circulates in discussion. The Incretins repeats a sponsor human measurement. Half-life means the amount in the body falls by half; it does not measure felt duration. Community guide

Onset: when changes were noticed

Appetite changes in the first week of one trial diary. After a May 1 first injection, the May 8 post described almost no appetite. Headache around two hours and sulfur burps around 30 hours after injection were adverse-symptom timings, not weight-loss onset measurements. The headache reportedly resolved after drinking water. Personal report

Duration: how long appetite effects last

Near two weeks in one missed-dose account; a full month remains unclear. The same author reported appetite control after missing a weekly visit for travel, approaching two weeks since the last injection. Prior repeated doses prevent calling this a single-dose measurement or monthly curve. Personal report

Cycles and maintenance

One diary describes 12 weekly weeks followed by monthly visits. This reported study schedule concerns ongoing maintenance. These reports establish no community on/off cycle. A four-week injection interval is not a four-week course. Personal report Reddit r/GLP1ResearchTalk Community

Cautions that matter

A quieter appetite can become food aversion. The early diary describes difficulty finding tolerable foods, brief queasiness and sulfur burps lasting about 24 hours. Recently weaning a child also confounded weight changes. Personal report
A long-lasting injection raises a practical worry. A monthly-shot reply worries about being stuck with uncomfortable effects; another asks whether appetite suppression will be excessive early and weak late in the month. These are questions, not demonstrated month-long symptom patterns. Reddit r/GLP1ResearchTalk
Trial nausea, vomiting and diarrhea still occurred. Pfizer described predominantly mild or moderate events, with severe nausea or vomiting possible. Comparisons with Zepbound from separate trials cannot establish which is better tolerated. Official context
No approved regimen or community preparation standard. The existing record identifies an unapproved candidate and no established community preparation guidance. Trial administration does not validate a separately labeled product or establish long-term safety. Community Official context

What the trial accounts add

The first monthly dose was rough for one reply author. Reply author hanuh_conda called the first monthly dose rough, without specifying symptoms or duration. The original author reported feeling well. These distinct voices show variation, not its frequency. Personal report
The VESPER-4 report is a different, blinded account. The German article relays 93 to 89.2 kg over five weeks, occasional fullness and fatty-meal heartburn. Dose and placebo status were unknown; this AI-assisted retelling cannot establish monthly experience. GLP-1 Forum Germany
Symptoms cannot reveal the blinded assignment. The early author believed they had active treatment. An unchanged-weight reply explicitly concerned an Amgen trial, not Berobenatide. Neither sulfur burps nor absent symptoms verifies treatment assignment. Personal report

Study context behind the circulating numbers

Human half-life: approximately 380 hours, or 15–16 days. Metsera's filing reports this after a single subcutaneous dose. It is a preliminary sponsor result, separate from felt duration. Official context
Weekly and monthly quantities belong to different study designs. VESPER-3 used 0.4–1.2 mg weekly steps before 3.2 or 4.8 mg monthly. Pfizer separately discussed 1.6 mg weekly in VESPER-2 and 2.4 mg weekly in VESPER-1. These are per-injection amounts, not daily totals or an interchangeable regimen. Official context Official context
Weight and blood-sugar headlines answer different questions. Pfizer reported 15.9% weight loss over a 32-week extension, ending at overall week 60, without placebo adjustment. VESPER-2 reported a 2.2-percentage-point HbA1c fall versus 0.2 on placebo. HbA1c reflects longer-term blood sugar; neither result predicts an individual's weight loss. Official context
12.3% and 10.5% describe different analyses of the same monthly arm. At week 28, the 4.8 mg VESPER-3 arm's placebo-adjusted figures differed according to whether the analysis focused on treatment adherence or included measurements despite discontinuation. They are not two independent success rates. Official context